Company Overview - Beijing RMT Medical Technology Co., Ltd. was established in 2001 and successfully listed on the Shenzhen Stock Exchange's Growth Enterprise Market on November 1, 2022 [2] - The company specializes in providing comprehensive treatment solutions for OSA and COPD patients, focusing on home non-invasive ventilators and ventilation masks [2] - RMT is the first domestic company to have non-invasive ventilator products certified by the FDA, with sales in over 100 countries [2] Research and Development - As of December 31, 2024, the company holds 633 valid patents in China, including 107 invention patents, 390 utility model patents, and 136 design patents [3] - The company also has 202 valid overseas patents, including 39 in the United States and 30 in Europe [3] Financial Performance - In Q1 2025, the company's overseas revenue reached 170 million CNY, a year-on-year increase of 35.48%, while domestic revenue was 96 million CNY, with a quarter-on-quarter growth of 48.79% and a year-on-year growth of 43.03% [4] - The gross margin for domestic operations was 51.51%, and for overseas operations, it was 48.47%, with both showing an increase compared to the previous quarter [4] Product Launches and Market Strategy - The newly launched P5 series ventilators are primarily targeted at domestic hospital channels, which have a relatively high gross margin [4] - The introduction of the RMT oxygen bottle marks a strategic shift towards the consumer goods market, enhancing brand influence and market share [5] Brand Development - The company's rebranding to "RMT" signifies a strategic alignment between product and capital markets, aiming to enhance brand value [5] - The name "RMT" reflects the company's commitment to respiratory health and smart technology, creating a unified identity across products and capital markets [5] Market Expansion - The company has made adjustments to domestic channel policies and sales strategies, resulting in improved revenue and gross margins in Q1 2025 [5] - In Europe, the company has completed the construction of its cloud platform and is onboarding agents, laying the groundwork for future growth in the mainstream medical insurance market [5]

Company Overview - Beijing Ruimait Medical Technology Co., Ltd. was established in 2001 and launched its first multi-channel sleep monitor in 2003. The company went public on the Shenzhen Stock Exchange's Growth Enterprise Market on November 1, 2022 [2][3]. - The company specializes in providing comprehensive treatment solutions for OSA and COPD patients, covering diagnosis, treatment, and chronic disease management [2][3]. - Ruimait is a leading domestic company in home non-invasive ventilators and masks, with products sold in over 100 countries and regions, holding multiple certifications including NMPA, FDA, and CE [2][3]. Research and Development - As of December 31, 2024, the company holds 633 valid patents in China, including 107 invention patents, 390 utility model patents, and 136 design patents. It also has 202 valid overseas patents [3]. Market Position - Ruimait's home non-invasive ventilators hold a 30.6% market share in China, ranking first, and a 12.4% share globally, ranking second in the industry [4][5]. Brand Strategy - The rebranding to "Ruimait" signifies a strategic alignment between product identity and capital market perception, enhancing brand value and market penetration [4][5]. - The name "Ruimait" combines "respiratory" and "smart," reflecting the company's commitment to respiratory health and innovative technology [5]. Product Development - The launch of the Ruimait oxygen bottle marks the company's entry into the consumer goods market, featuring a unique mechanical valve design that enhances oxygen utilization [6]. - The collaboration with Shenzhen Hanyu Pharmaceutical Co., Ltd. aims to develop new products for health consumer channels, targeting mild sleep disorder populations [6][7]. Market Expansion - The company is enhancing its domestic channel strategies and has seen improvements in revenue and gross margin in the first quarter [7][8]. - In Europe, the company has established a cloud platform and onboarded over 20 agents, laying the groundwork for future growth in the mainstream medical insurance market [8].

Core Viewpoint - The company has shown a recovery in performance with Q1 2025 results exceeding expectations, driven by improved order fulfillment in the U.S. market and ongoing domestic growth initiatives [1][3][10] Financial Performance - For 2024, the company reported revenue of 843 million yuan (down 24.85%), net profit attributable to shareholders of 155 million yuan (down 47.74%), and net profit excluding non-recurring items of 92 million yuan (down 61.79%) [2][3] - In Q1 2025, revenue reached 265 million yuan (up 38.11%), net profit attributable to shareholders was 72 million yuan (up 44.11%), and net profit excluding non-recurring items was 60 million yuan (up 43.18%) [2][4] Market Outlook - The company anticipates continued growth in Q2 2025, particularly in the U.S. market, as the low base effect from the previous year supports performance [1][5] - The company plans to enhance brand promotion and channel development in both domestic and international markets throughout the year [1][5][10] Business Segmentation - Revenue from home respiratory therapy products in 2024 was 527 million yuan (down 38.15%), while consumables revenue was 284 million yuan (up 46.22%) [4] - In Q1 2025, home respiratory therapy revenue was 176 million yuan (up 62.80%), and consumables revenue was 81 million yuan (up 7.46%) [4][9] Brand Development - The company changed its name from "怡和嘉业" to "瑞迈特" on May 21, aiming to enhance brand influence and align its corporate identity with its core product offerings [2][5][6] R&D and Innovation - The company is committed to maintaining high levels of R&D investment to improve product performance and expand market share [1][5][10] - Future innovations in respiratory products are expected to leverage AI and brain-machine interface technologies for enhanced functionality [6] Incentive Plans - The company announced a stock incentive plan for 2025, aiming to grant up to 704,000 restricted shares to 54 key personnel, with performance targets set for revenue growth [7]

证券代码：301367 证券简称：瑞迈特 北京瑞迈特医疗科技股份有限公司 投资者关系活动记录表 编号：2025—007 | | □特定对象调研 □ 分析师会议 | | | | --- | --- | --- | --- | | 投资者关系活动 | □ 媒体采访 □业绩说明会 | | | | 类别 | □ 新闻发布会 √路演活动 | | | | | □现场参观 | | | | | □其他 | | | | 参与单位名称 | 详见附件清单 | | | | 时间 | 2025 年 5 月 22 日-2025 年 月 23 日 | 5 | | | 地点 | 深圳、北京 | | | | 上市公司接待人 | 副总经理兼董事会秘书：杜祎程 | | | | 员姓名 | 证券事务代表：刘士岩 | | | | | 一、公司简要介绍 | | | | | 公司 2001 年成立，2003 年第一台多导睡眠监测仪上市，2007 | | | | | 年第一台 CPAP 睡眠呼吸机上市，2008 年通过 CE 认证，2012 | | 年 | | | 通过美国 认证，2016 年 新品牌成立，同年呼吸数据管 FDA BMC | | | | | ...

重要的消息有哪些 潘功胜主持召开金融支持实体经济座谈会 5月19日，中国人民银行行长潘功胜主持召开金融支持实体经济座谈会并讲话。金融监管总局副局长周亮出席会议并讲话。中国人民银行副行长宣昌能、邹 澜出席会议。 会议强调，要实施好适度宽松的货币政策，满足实体经济有效融资需求，保持金融总量合理增长。加力支持科技创新、提振消费、民营小微、稳定外贸等重 点领域，用好用足存量和增量政策，提高金融支持实体经济质效，支持经济结构调整、转型升级和新旧动能转换。强化货币政策执行和传导，维护市场竞争 公平秩序，推动金融服务实体经济和银行自身可持续发展的有机统一。有序推进人民币国际使用，提高贸易和投融资便利化水平。统筹发展和安全，坚决维 护国家金融安全。 前4个月公共财政收入累计降幅继续收窄 中央收入月度增幅由负转正 财政部公布2025年1—4月财政收支情况，印花税1614亿元，同比增长18.9%。其中，证券交易印花税535亿元，同比增长57.8%。 国家能源局：4月份全社会用电量7721亿千瓦时，同比增长4.7% 国家能源局5月20日发布4月份全社会用电量等数据。4月份，全社会用电量7721亿千瓦时，同比增长4.7%。1—4月， ...

Key Points - China Shipbuilding Industry Corporation plans to achieve operating revenue exceeding 60 billion yuan by 2025, with a record high backlog of orders exceeding 1.4 billion yuan and over 30 million deadweight tons of civil ship orders [2] - The company has a production schedule extending to the end of 2028, with 90% of new orders being bulk orders for main ship types and nearly 60% of civil ship orders being green ship types [2] IPO Issuance Dynamics - Chao Hong Ji is planning to issue H-shares on the Hong Kong Stock Exchange, with details yet to be determined, while its operational status remains normal [4] - Zhaoyi Innovation intends to issue H-shares and list on the Hong Kong Stock Exchange, considering the interests of existing shareholders and market conditions [5] Refinancing Dynamics - Jiu Hua Tourism plans to issue A-shares to specific investors, raising up to 500 million yuan for various projects, including upgrades to hotel facilities and transportation equipment [7] - Yue Gui Co. intends to raise up to 900 million yuan through a private placement of A-shares for several development projects [8] Regulatory Compliance Dynamics - Star Technology received a regulatory letter from the Shenzhen Stock Exchange for inaccurate revenue recognition in its financial reports, affecting reported revenues by 12 million yuan and 170 million yuan for the half-year and third-quarter reports, respectively [10] - ST Huaxi's controlling shareholder has been detained and is under investigation, but the company's operations remain normal [11] Company Announcements - Jie Hua Te plans to acquire a 40.89% stake in Tianyi Hexin for 319 million yuan, enhancing its product line in the signal chain category [14] - Zhongjin Environment has changed its name to "Nanfang Pump Industry," aligning its name with its main business [15] - Yi He Jia Ye has changed its name to "Rui Mai Te," reflecting its business and development strategy [16] - Zhongnong Lihua intends to acquire at least 50% of Taizhou Agricultural Resources, which will become a subsidiary [17] - Weiling Co. successfully acquired a 74.3% stake in Jiayu Mining for 220 million yuan, expanding its presence in the non-ferrous metal resources sector [18] - Yuanxing Energy has changed its name to "Bohua Chemical," aligning its name with its main business [19] - Gansu Energy reported a safety incident at its Wangjiashan coal mine, resulting in three fatalities, but overall operations remain unaffected [20] - Huili B's stock may be delisted due to a market capitalization below 300 million yuan [21] - Kangda New Materials plans to sell a 51% stake in Chengdu Biko Technology for 188 million yuan, constituting a related party transaction [22] - Andeli has terminated its plan to issue A-shares due to the disqualification of its securities service provider [23]

重要的消息有哪些 潘功胜主持召开金融支持实体经济座谈会 5月19日，中国人民银行行长潘功胜主持召开金融支持实体经济座谈会并讲话。金融监管总局副局长周 亮出席会议并讲话。中国人民银行副行长宣昌能、邹澜出席会议。 会议强调，要实施好适度宽松的货币政策，满足实体经济有效融资需求，保持金融总量合理增长。加力 支持科技创新、提振消费、民营小微、稳定外贸等重点领域，用好用足存量和增量政策，提高金融支持 实体经济质效，支持经济结构调整、转型升级和新旧动能转换。强化货币政策执行和传导，维护市场竞 争公平秩序，推动金融服务实体经济和银行自身可持续发展的有机统一。有序推进人民币国际使用，提 高贸易和投融资便利化水平。统筹发展和安全，坚决维护国家金融安全。 前4个月公共财政收入累计降幅继续收窄 中央收入月度增幅由负转正 财政部5月20日公布的数据显示，1—4月全国一般公共预算收入80616亿元，同比下降0.4%，降幅比一 季度收窄0.7个百分点。分中央和地方看，中央一般公共预算收入下降3.8%，降幅比一季度收窄1.9个百 分点，其中4月中央收入增长1.6%，今年以来首月实现正增长；地方一般公共预算收入增长2.2%，增幅 与一季度持 ...

2025.05. 20 5月20日晚间，沪深两市多家上市公司发布公告，以下是第一财经对一些重要公告的汇总，供投资者 参考。 【品大事】 兆易创新：拟发行H股股票并在香港联交所主板挂牌上市 兆易创新(603986)公告，公司拟发行境外上市外资股（H股）股票并在香港联交所主板挂牌上市。公 司将充分考虑现有股东的利益和境内外资本市场的情况，在股东会决议有效期内选择适当的时机和发 行窗口完成此次发行并上市。 *ST中地：放弃嘉庚科艺城地块项目商业机会 *ST中地(000736)公告，公司近期获悉厦门市集美区J2025P01号嘉庚科艺城地块项目的商业机会，项 目土地面积10.86万平方米，为商住用地，计容建筑面积约17.40万平方米，项目挂牌起始价为20.67 亿元。通过对上述商业机会的考察，结合公司目前的经营情况，公司拟放弃此次商业机会。如果公司 放弃此次商业机会，公司控股股东中交房地产集团有限公司或其下属公司（统一简称"地产集团"）将 对该项目进行后续开发建设，地产集团与公司将签订代为业务培育协议，约定在该项目条件成熟时再 由公司决定是否行使优先收购权。 西昌电力：分时电价机制调整 预计减少公司2025年净利润约5 ...

受名称变更的影响，仍将按约定的内容履行。 北京怡和嘉业医疗科技股份有限公司董事会 证券代码：301367 证券简称：怡和嘉业 公告编号：2025-043 北京怡和嘉业医疗科技股份有限公司 关于变更公司名称、证券简称暨完成工商变更登记的公 告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 重要提示： 怡和嘉业医疗科技股份有限公司"变更为"北京瑞迈特医疗科技股份有限公司"。 日。 一、公司变更公司名称、证券简称的情况 公司名称、证券简称及修订 <公司章程> 的议案》，上述议案已经公司于 2025 年 5 月 13 日召开 2024 年年度股东大会审议通过，具体内容详见公司于 2025 年 4 月 18 日、2025 年 5 月 14 日于巨潮资讯网（http://www.cninfo.com.cn）披露的相关公告。 公司变更中文名称、证券简称，公司英文名称及证券代码保持不变。具体情况如下： 变更前 变更后 中文名称 北京怡和嘉业医疗科技股份有限公司 北京瑞迈特医疗科技股份有限公司 英文名称 BMC Medical Co., Ltd. BMC Medical Co ...

证券代码：301367 证券简称：怡和嘉业 公告编号：2025-042 按公司总股本（含回购股份）折算的每 10 股现金分红金额（含税）=本次实际现金 分红总额/公司总股本*10 股=35,548,928/89,600,000*10=3.967514 元（保留六位小数，最 后一位直接截取，不四舍五入）；本次权益分派实施后的除权除息参考价=除权除息前 一交易日收盘价-按公司总股本折算的每股现金分红的金额=除权除息前一交易日收盘 价-0.3967514 元/股（按公司总股本折算每股现金分红金额，不四舍五入）。 一、股东大会审议通过利润分配方案情况 东大会，审议通过了《关于公司 2024 年度利润分配预案的议案》，公司 2024 年度利润 分配方案如下：以公司现有总股本 8,960 万股扣减不参与利润分配的回购专用证券账户 的股份 727,680 股，即 88,872,320 股为基数，向全体股东每 10 股派发现金股利人民币 元（含税）。剩余未分配利润结转以后年度分配。在第三届董事会第十三次会议召开后 至实施利润分配的股权登记日前，如公司总股本发生变动的，公司拟按照分配比例不变 的原则对派发总额进行调整。 二、本 ...